

HERO Community Testing: Summary Report


published May 14, 2021

The <u>Utah Health and Economic Recovery Outreach (HERO) Project</u> began in May 2020 as a collaborative statewide testing and analysis project to understand the community-based spread of Covid-19. The goal of the HERO Project is to collect and analyze high-quality data on community behaviors, antibody prevalence, infection in schools, economic activity, and attitudes about vaccination, all to help inform decision-makers seeking to guide Utah's citizens and economy through the pandemic and aid a safe return to normalcy. Beginning in March 2021, the project team is publishing regular update reports on each of these topics of interest. This report summarizes <u>previous reporting</u> on the <u>HERO Project's</u> statewide community-based testing between May 2020 and April 2021.

Background

Community testing has served as the core of the HERO Project's work between May 2020 and April 2021. The team has run several rounds of testing and analysis throughout these 12 months and published findings throughout the process. Community testing included testing for antibodies due to Covid-19 infection, antibodies demonstrating vaccine response, surveys of behavior, and testing for current or recent infection.

Overview of HERO Project community testing (2020 - 2021)



^{* &}quot;Co." = abbreviation for county/counties

^{**} location selected for high rates of Covid-19 transmission in certain hotspot(s)


Testing Results

Antibody Positivity

Antibody testing measures an immune system response caused either by prior Covid-19 infection or vaccination. The presence of antibodies is associated with at least partial immunity to future infection for several months or longer. The prevalence of positive antibody tests has risen in most groups and settings throughout the pandemic, reflecting an increase in total infections. However, over time, antibody tests begin to miss the presence of antibodies in a small proportion of people, making the measurement complex.

As displayed below, antibody prevalence began to increase in fall 2020 in parallel with Utah's case count. The total prevalence of antibodies grew more rapidly in winter and spring as vaccines became more widely available. Tracking antibody prevalence tracks the progress towards herd immunity, or the range at which transmission will cease or fall to very low levels (estimated at 75-90% immune).

Estimated total antibody positivity among tested respondents*



^{*} Derived from HERO Project testing using the EuroImmun test, these results are specifically representative of the testing periods and locations shown in the timeline above.

Detection Fraction

Detection fraction is an estimate of how well clinical testing and reporting of cases capture the true total number of cases as estimated by antibody prevalence. Essentially, this is a measure of the effectiveness of state testing procedures at capturing cases within the community. At the beginning of the pandemic, the detection fraction was fairly low: testing and reporting captured 40% of the true number of infections. In other words, for every 1 case detected by testing and reporting, about 1.5 cases were undetected. This rate fluctuated substantially in different geographies and time periods but converged to approximately 60% in the last several months of testing. This means that for every case detected, less than one was missed. However, as noted in a previous report, the detection fraction was substantially lower for children younger than 12 years of age, meaning that a greater number of cases are missed among youth.

Overall, the detection fraction for Utah indicates that a substantially higher proportion of cases were detected through surveillance in the state than occurred in the rest of the US, as reporting from the Centers for Disease Control and Prevention suggests that nationwide, testing efforts may have only detected 1 of every 4 actual cases.

Next Steps

In the twelve months since May 2020, the HERO Project has been conducting testing and analysis to better understand transmission of the Covid-19 virus in communities throughout Utah. The HERO team has conducted nearly 40,000 tests on nearly 30,000 individuals, assisted policymakers in well-informed decision making, and developed a deep understanding of the simultaneous effectiveness of Utah's response thus far and the need for continued protective measures like vaccination and mask-wearing. Moving forward, the HERO Project will be transitioning to focus on vaccine uptake, circumstances and implications in Utah's long-term care facilities, and continuing testing in K-12 schools. These efforts reflect the HERO Project's dedication to meeting the shifting needs of Utah's public health and economic contexts, and to continue informing policymakers and the general public as the state enters the next phase of recovery.

Acknowledgments

Leading the HERO Project are Stephen C. Alder, PhD; Adam Looney, PhD; and Matt Samore, MD. The project is funded by the State of Utah in coordination with the Governor's Office of Management and Budget and the Utah Department of Health.

Senior advisors to the project are Taylor Randall, MBA, PhD; Natalie Gochnour, MS; and Michael Good, MD. The Project team is Andrew T. Pavia, MD; Julio Delgado, MD, MS; Adam Hersh, MD; Krow Ampofo, MD; and Tom Greene, PhD. The following teams and centers supported the project:

Center for Clinical & Translational Science Study Design and Biostatistics Center

Brian Orleans, MS
Gentry Carter
Angela Presson, PhD
Chong Zhang, MS
Jian Ying, PhD
Chelsea Allen, PhD
Andrew Redd, PhD
Molly Mcfadden, MS
Ben Brintz, PhD
Tyler Bardsley, MS
Yue Zhang, PhD
Jincheng Shen, PhD
Zhining Ou

Division of Epidemiology

Kristina Stratford, PMP, CCRP Tavis Huber Molly Leecaster, PhD Candace Haroldsen, BS Xiangyang Ye, PhD

Marriner S. Eccles Institute for Economics and Quantitative Analysis

Nathan Seegert, PhD Mac Gaulin, PhD MJ Yang, PhD

University of Utah Health Clinical Operations

Michael Bronson, JD, MBA Nikki Gilmore, MSN, RN Christina Butterfield, MSN, RN David Ence, MHSA

Survey Design and Measurement Core

Morgan Millar, PhD

Utah HERO Project Team

Alicen Bringard, MPA
Elizabeth Rabon, MA
Jill Stephenson, MPA
Soumava Basu, PhD
Jeanette Nelson, PhD
Christopher "Kit" Fry
Jonathan Frehner
Jamon Winegar
Devin Ostler
Annie Smith
Hannah Crane
Braden Card
Maddison Dillon
Cassie Cowdell

The Church of Jesus Christ of Latter-Day Saints generously contributed the use of their parking lots and buildings to support mobile testing for this project. In addition, we thank the HERO Project's field team that has staffed and supported countless testing events across the state. We also appreciate the support of the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002538.

This report was developed by the Sorenson Impact Center at the University of Utah's David Eccles School of Business in partnership with the HERO Project leadership. Sorenson Impact works with public, nonprofit, and private sector stakeholders to develop, structure, and mobilize capital for innovative and data-driven approaches to difficult social and public health challenges. This report was created by Austin Hendrickson and Allison Nicholson and designed by Alicia Pangman.

For more information about this report, contact <u>Elizabeth Rabon</u>, Associate Director of Administration of the Center for Business, Health, and Prosperity at the University of Utah.









